Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
Incyte reported positive results from its pivotal Phase 3 frontMIND trial, showing that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in patients with previously untreated, high-risk DLBCL. The combination therapy reduced the risk of disease progression or death by 25% compared to R-CHOP alone (HR 0.75, p=0.0194), with a 2-year PFS rate of 71.1% versus 62.9% for the control arm.
Key figures
- Drug Name
- tafasitamab (Monjuvi/Minjuvi)
- Phase Of Trial
- Phase 3
- Os p value
- 0.2703
- Efs p value
- 0.026
- Pfs p value
- 0.0194
- Os hazard ratio
- 0.85
- Efs hazard ratio
- 0.79
- Enrollment count
- 899
- Pfs hazard ratio
- 0.75
- Pfs risk reduction
- 25%
- Pfs 2yr rate control
- 62.9%
- Pfs 3yr rate control
- 60.7%
- Pfs 2yr rate treatment
- 71.1%
- Pfs 3yr rate treatment
- 67.3%
- Median follow up months
- 35.2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.